Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Partner of crime boss Steven Lyons arrested in Dubai - 2New materials, old physics – the science behind how your winter jacket keeps you warm
- 3Doctors looking into hormone therapy as a way to ward off dementia in women
- 4Vote in favor of Your Number one Cake Type
- 5Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- Step by step instructions to Shield Your Wellbeing Around 5G Pinnacles\
- Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 18
- Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- German unemployment rate falls to 6.4%, but 3 million still jobless
- The most effective method to Pick the Right Teeth Substitution Choice for You
- Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- Eurasian cargo hub expands to capture Europe-Asia freight flows
- 'The Real Housewives of Rhode Island' 1st teaser trailer unveiled: Which Bachelor Nation star is part of the cast? And when does it premiere?
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
